Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir

被引:28
作者
Ford, SL
Wire, MB
Lou, Y
Baker, KL
Stein, DS
机构
[1] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA
[2] Aventis Pharmaceut, Bridgewater, NJ USA
关键词
D O I
10.1128/AAC.49.1.467-469.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Single doses of MAALOX TC and ranitidine were administered separately with 1,400 ling of fosamprenavir (FPV). MAALOX TC decreased the area under the concentration-time curve from 0 to 24 h (AUC(0-24)) for plasma amprenavir (APV) by 18% and the maximum concentration of drug in serum (C-max) by 35%; the plasma APV concentration at 12 h (C,2) increased by 14%. Ranitidine at 300 mg decreased the AUC(0-24) for plasma APV by 30% and C-max by 51%; C-12 was unchanged. FPV may be coadministered with antacids without concern and without separation in dosing; however, caution is recommended when FPV is coadministered with histamine(2)-receptor antagonists or proton pump inhibitors.
引用
收藏
页码:467 / 469
页数:3
相关论文
共 12 条
[1]   Indinavir concentrations and antiviral effect [J].
Acosta, EP ;
Henry, K ;
Baken, L ;
Page, LM ;
Fletcher, CV .
PHARMACOTHERAPY, 1999, 19 (06) :708-712
[2]  
*BRIST MYERS SQUIB, 2004, REYETAZ AT SULF PROD
[3]  
*BRIST MYERS SQUIB, 2004, VIDEX DID PROD INF
[4]   Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy [J].
Fletcher, CV ;
Brundage, RC ;
Remmel, RP ;
Page, LM ;
Weller, D ;
Calles, NR ;
Simon, C ;
Kline, MW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1029-1034
[5]   Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir [J].
Furfine, ES ;
Baker, CT ;
Hale, MR ;
Reynolds, DJ ;
Salisbury, JA ;
Searle, AD ;
Studenberg, SD ;
Todd, D ;
Tung, RD ;
Spaltenstein, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :791-798
[6]   Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine [J].
Haas, DW ;
Arathoon, E ;
Thompson, MA ;
Pedro, RD ;
Gallant, JE ;
Uip, DE ;
Currier, J ;
Noriega, LM ;
Lewi, DS ;
Uribe, P ;
Benetucci, J ;
Cahn, P ;
Paar, D ;
White, CA ;
Collier, AC ;
Ramirez-Ronda, CH ;
Harvey, C ;
Chung, M ;
Mehrotra, D ;
Chodakewitz, J ;
Nguyen, BY .
AIDS, 2000, 14 (13) :1973-1978
[7]  
LORENZI P, 1997, AIDS, V11, P95
[8]   Ordered accumulation of mutations in HIV protease confers resistance to ritonavir [J].
Molla, A ;
Korneyeva, M ;
Gao, Q ;
Vasavanonda, S ;
Schipper, PJ ;
Mo, HM ;
Markowitz, M ;
Chernyavskiy, T ;
Niu, P ;
Lyons, N ;
Hsu, A ;
Granneman, GR ;
Ho, DD ;
Boucher, CAB ;
Leonard, JM ;
Norbeck, DW ;
Kempf, DJ .
NATURE MEDICINE, 1996, 2 (07) :760-766
[9]   Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing [J].
Sadler, BM ;
Gillotin, C ;
Lou, Y ;
Stein, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :30-37
[10]   A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir) [J].
Stein, DS ;
Fish, DG ;
Bilello, JA ;
Preston, SL ;
Martineau, GL ;
Drusano, GL .
AIDS, 1996, 10 (05) :485-492